abstract |
The present invention relates to a compound that has URAT1 inhibitory action, and a URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition comprising the compound. More specifically, the present invention relates to a compound represented by Formula (I) below. n n n n n n n n n n [in the formula,n R 1 is -Q 1 -A 1 and the like; is a double bond or a single bond; when is a double bond, W 1 is a nitrogen atom or a group represented by the general formula: ═C(R a )—, and W 2 is a nitrogen atom or a group represented by the general formula: ═C(R b )—; when is a single bond, W 1 is a group represented by the general formula: —C(R aa )(R ab )— or a group represented by the general formula: —(C═O)—, and W 2 is a group represented by the general formula: —C(R ba )(R bb )—, a group represented by the general formula: —(C═O)— or a group represented by the general formula: —N(R bc )—; W 3 , W 4 and W 5 are each independently a nitrogen atom or a methine group and the like that may have a substituent; X is a single bond, an oxygen atom and the like; Y is a single bond or (CR Yi R Yi′ ) n ; and Z is a hydroxyl group or COOR 2 and the like. |